MilliporeSigma in Carlsbad, the U.S. Life Science division of Merck KGaA, operates a contract development and manufacturing organization for viral vector and gene therapy production across two facilities totaling over 200,000 square feet. The Carlsbad campus has manufactured viral vectors since 1997, producing adeno-associated virus and lentiviral vectors at scales up to 1,000 liters using Mobius® single-use bioreactor technology, a depth of GMP capability that positions the operation alongside HS Biopharmaceuticals, Inc. in Carlsbad's expanding pharmaceutical manufacturing corridor. The $110 million second facility at 2827 Whiptail Loop West opened in 2021, adding 140,000 square feet and more than doubling commercial-scale production capacity across 30 total cleanroom suites. BioReliance® CDMO services support customers developing gene therapies for neurological conditions including spinal muscular atrophy, supplying the viral vector platforms that work upstream from surgical interventions performed at UMD North County Neurosurgery. Suspension-based viral vector manufacturing at the 1,000-liter bioreactor scale uses single-use Mobius® equipment across ISO-classified cleanroom suites, enabling batch production from Phase I clinical trials through full commercial supply.